658 related articles for article (PubMed ID: 21317409)
21. Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients.
Graff J; Scheuermann EH; Brandhorst G; Oellerich M; Gossmann J
Ther Drug Monit; 2016 Jun; 38(3):388-92. PubMed ID: 26829599
[TBL] [Abstract][Full Text] [Related]
22. Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium.
Jia Y; Peng B; Li L; Wang J; Wang X; Qi G; Rong R; Wang L; Qiu J; Xu M; Zhu T
Ther Drug Monit; 2017 Feb; 39(1):29-36. PubMed ID: 27941535
[TBL] [Abstract][Full Text] [Related]
23. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
[TBL] [Abstract][Full Text] [Related]
24. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients.
Kamar N; Rostaing L; Cassuto E; Villemain F; Moal MC; Ladrière M; Barrou B; Ducloux D; Chaouche K; Quéré S; Di Giambattista F; Be F
Clin Nephrol; 2012 Feb; 77(2):126-36. PubMed ID: 22257543
[TBL] [Abstract][Full Text] [Related]
25. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients.
de Winter BC; van Gelder T; Glander P; Cattaneo D; Tedesco-Silva H; Neumann I; Hilbrands L; van Hest RM; Pescovitz MD; Budde K; Mathot RA
Clin Pharmacokinet; 2008; 47(12):827-38. PubMed ID: 19026038
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients.
Perry TW; Christians U; Trotter JF; Bendrick-Peart J
Clin Transplant; 2007; 21(3):413-6. PubMed ID: 17488394
[TBL] [Abstract][Full Text] [Related]
28. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
Salvadori M; Holzer H; Civati G; Sollinger H; Lien B; Tomlanovich S; Bertoni E; Seifu Y; Marrast AC;
Clin Nephrol; 2006 Aug; 66(2):112-9. PubMed ID: 16939067
[TBL] [Abstract][Full Text] [Related]
29. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation.
Stracke S; Shipkova M; Mayer J; Keller F; Zarghom A; Yang L; Henne-Bruns D; Wieland E
Clin Transplant; 2012; 26(1):57-66. PubMed ID: 21299636
[TBL] [Abstract][Full Text] [Related]
31. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials.
Pietruck F; Budde K; Salvadori M; Sollinger H; Bourbigot B; Gentil MA; Oppenheimer F
Clin Transplant; 2007; 21(1):117-25. PubMed ID: 17302600
[TBL] [Abstract][Full Text] [Related]
33. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
[TBL] [Abstract][Full Text] [Related]
34. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
[TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Exposure in Chinese Renal Allograft Recipients After Administration of EC-MPS.
Chen B; Shao K; An HM; Shi HQ; Lu JQ; Zhai XH; Liu XX; Wang XH; Xu D; Zhou PJ
J Clin Pharmacol; 2019 Apr; 59(4):578-589. PubMed ID: 30537048
[TBL] [Abstract][Full Text] [Related]
36. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.
Weber LT; Hoecker B; Armstrong VW; Oellerich M; Tönshoff B
Ther Drug Monit; 2006 Oct; 28(5):623-31. PubMed ID: 17038876
[TBL] [Abstract][Full Text] [Related]
37. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium.
de Winter BC; van Gelder T; Mathot RA; Glander P; Tedesco-Silva H; Hilbrands L; Budde K; van Hest RM
Ther Drug Monit; 2009 Oct; 31(5):585-91. PubMed ID: 19704401
[TBL] [Abstract][Full Text] [Related]
38. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring.
Budde K; Tedesco-Silva H; Pestana JM; Glander P; Neumayer HH; Felipe CR; Machado PP; Sechaud R; Schmouder R
Ther Drug Monit; 2007 Jun; 29(3):381-4. PubMed ID: 17529899
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the area under the curve of enteric-coated mycophenolate sodium using a limited sampling strategy in Chinese kidney transplant recipients
.
Huang H; Yao X; Wu J; Peng W; Chen J
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):138-146. PubMed ID: 27781422
[TBL] [Abstract][Full Text] [Related]
40. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
Burg M; Säemann MD; Wieser C; Kramer S; Fischer W; Lhotta K
Transplant Proc; 2009 Dec; 41(10):4159-64. PubMed ID: 20005359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
